Q linea AB (QLINEA) - Net Assets
Based on the latest financial reports, Q linea AB (QLINEA) has net assets worth Skr338.00 Million SEK (≈ $36.37 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr369.67 Million ≈ $39.78 Million USD) and total liabilities (Skr31.66 Million ≈ $3.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Q linea AB (QLINEA) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr338.00 Million |
| % of Total Assets | 91.43% |
| Annual Growth Rate | 44.68% |
| 5-Year Change | -21.54% |
| 10-Year Change | 3898.14% |
| Growth Volatility | 10650.73 |
Q linea AB - Net Assets Trend (2015–2025)
This chart illustrates how Q linea AB's net assets have evolved over time, based on quarterly financial data. Also explore Q linea AB asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Q linea AB (2015–2025)
The table below shows the annual net assets of Q linea AB from 2015 to 2025. For live valuation and market cap data, see Q linea AB stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
+1331.07% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
-114.48% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
+17.33% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
-62.48% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
+13.31% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
+11.51% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
-33.60% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
+33858.86% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
-82.11% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
+0.55% |
| 2015-12-31 | Skr8.41 Million ≈ $904.84K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Q linea AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 160215300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.90 Million | 0.56% |
| Other Components | Skr2.03 Billion | 599.43% |
| Total Equity | Skr338.00 Million | 100.00% |
Q linea AB Competitors by Market Cap
The table below lists competitors of Q linea AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Solidion Technology Inc.
NASDAQ:STI
|
$34.47 Million |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
$34.47 Million |
|
Crypto Blockchain Industries SA
PA:ALCBI
|
$34.48 Million |
|
CrystalGenomics Inc
KQ:083790
|
$34.49 Million |
|
QTC Energy Public Company Limited
BK:QTC
|
$34.45 Million |
|
EON Resources Inc.
NYSE MKT:EONR
|
$34.45 Million |
|
Shanghai Material Trading Co Ltd B
SHG:900927
|
$34.44 Million |
|
North Energy ASA
OL:NORTH
|
$34.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Q linea AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -27,456,000 to 338,004,000, a change of 365,460,000.
- Net loss of 182,485,000 reduced equity.
- Share repurchases of 588,882,000 reduced equity.
- New share issuances of 588,882,000 increased equity.
- Other comprehensive income decreased equity by 1,312,000.
- Other factors increased equity by 549,257,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-182.49 Million | -53.99% |
| Share Repurchases | Skr588.88 Million | -174.22% |
| Share Issuances | Skr588.88 Million | +174.22% |
| Other Comprehensive Income | Skr-1.31 Million | -0.39% |
| Other Changes | Skr549.26 Million | +162.5% |
| Total Change | Skr- | % |
Book Value vs Market Value Analysis
This analysis compares Q linea AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 46.54x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr0.36 | Skr16.90 | x |
| 2017-12-31 | Skr0.06 | Skr16.90 | x |
| 2018-12-31 | Skr35.27 | Skr16.90 | x |
| 2019-12-31 | Skr14.88 | Skr16.90 | x |
| 2020-12-31 | Skr15.02 | Skr16.90 | x |
| 2021-12-31 | Skr15.26 | Skr16.90 | x |
| 2022-12-31 | Skr5.53 | Skr16.90 | x |
| 2023-12-31 | Skr2.88 | Skr16.90 | x |
| 2024-12-31 | Skr-0.03 | Skr16.90 | x |
| 2025-12-31 | Skr50.75 | Skr16.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Q linea AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -53.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1644.31%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.09x
- Recent ROE (-53.99%) is above the historical average (-573.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -710.80% | -74186.42% | 0.00x | 1.99x | Skr-60.94 Million |
| 2017 | -4489.35% | -4525.27% | 0.08x | 12.17x | Skr-68.03 Million |
| 2018 | -25.00% | -12040.62% | 0.00x | 1.05x | Skr-179.70 Million |
| 2019 | -52.23% | -17717.41% | 0.00x | 1.10x | Skr-212.15 Million |
| 2020 | -57.91% | -90613.58% | 0.00x | 1.08x | Skr-258.21 Million |
| 2021 | -54.13% | -2497.94% | 0.02x | 1.08x | Skr-276.26 Million |
| 2022 | -170.62% | -2156.47% | 0.06x | 1.28x | Skr-291.93 Million |
| 2023 | -120.95% | -5165.90% | 0.02x | 1.22x | Skr-248.33 Million |
| 2024 | 0.00% | -9181.67% | 0.02x | 0.00x | Skr-214.13 Million |
| 2025 | -53.99% | -1644.31% | 0.03x | 1.09x | Skr-216.29 Million |
Industry Comparison
This section compares Q linea AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Q linea AB (QLINEA) | Skr338.00 Million | -710.80% | 0.09x | $34.46 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, includin… Read more